OVERVIEW

New Developments in Insulin Therapy: Expert Insights in Individualizing Treatment is organized by Tarsus CNS.

Program Description:
Despite well-established treatment guidelines, many patients with T2DM are not managed optimally and fail to achieve recommended levels of blood glucose control. Delays in initiating insulin, however, are common and may stem from both physician and patient barriers. Negative patient perceptions regarding insulin include complicated dosing regimens, fear of injections, and hypoglycemia. Clinician concerns include hypoglycemia, weight gain, and the misconception that elevated insulin increases cardiovascular risks.
This activity will bring clinicians up to date on the latest available and emerging options in basal insulin therapy, alone and in combination with other antidiabetic agents. To help clinicians address the unmet needs of patients in this area, expert faculty will discuss common barriers to the initiation of and adherence to insulin therapy as well as strategies to overcome these barriers, including how to help patients successfully utilize new insulin delivery systems and technology designed to make therapy simpler and more convenient.

Educational Objectives:
Upon completion of this activity, participants should be able to:
• Develop clinical strategies for the timely initiation and intensification of insulin therapy to achieve glycemic control.
• List common patient barriers that limit the effectiveness of insulin-mediated glucose control and take steps to overcome them.
• Discuss clinical outcomes data on new and emerging insulin formulations and combination insulin/incretin therapies, including pharmacological profiles surrounding efficacy and safety, such as effects on hypoglycemia and nocturnal hypoglycemia.
• Integrate novel insulin therapies, combination therapies, and technologies into clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, improve cardiovascular outcomes, and increase acceptance and adherence for patients.

Additional details will be posted as soon as they are available.

FACULTY

Athena Philis-Tsimikas

MDEndocrinology, Metabolism and Diabetes, Internal Medicine

Bernard Zinman

OC, MDCM, FRCPC, FACPEndocrinology, Metabolism and Diabetes, Research and Clinical Research

Anne Peters

MDInternal Medicine

Jean-Francois Yale

MD, CSPQ, FRCPCEndocrinology, Metabolism and Diabetes

SPECIALITIES

Endocrinology, Metabolism and Diabetes

CANCELLATION & REFUND POLICY

This is our canceling policy

Cancellations must be submitted in writing. If you are calling to cancel, for verification we will still require you to send an email to info@brainweek.org with your intent to cancel. You will receive confirmation of your cancellation via email.

We will offer a 100% refund within 72 hours from the time of purchase less $100 credit card processing fee.

After 72 hours, refunds will be less 50%. All refund requests must be made in writing and post marked or tax stamped no later than 90 days before the event.

No refund will be made if the request is made within 90 days of the educational event. Refunds will not be issued to non-show registrants.

Substitutions are always welcome in lieu of cancellation. No transfers to alternate events will be made if the request is submitted within 90 days of the original event.

Persons who register and fail to attend will not receive a refund. BRAINWeek, at its sole discretion, may transfer your registration to an upcoming conference or to a healthcare provider colleague. Cancellation of your conference registration does not automatically cancel your hotel room reservation. Please contact the hotel to cancel your room; penalties may apply.